Strategic Analysis

Measuring the strategic value of a business presentation is useful if the market has been understood and validated. What may seem a good value proposition can easily flounder if the market dynamics are not well investigated.

·Barriers to Entry – What are the the hurdles that need to be overcome to enter the market?

· Operating Freedom – Does the proposal actually have the freedom to achieve the claims it makes? Is there current IP which will stand in the way?

· Competitive Landscape – How intense is the competition? Does the market lend itself to pricing wars and therefore reduced margins? How will competitors react to a new entrant?

· Sustainability – Is the proposal sustainable? Will the competition simply produce a better mousetrap?

· Implementation – Is the proposal implementable? Is the business model appropriate to the situation and are the team’s skills sufficient to implement the model?

· R&D Value Creation – Is the proposal a “one off” or is there a pipeline of innovation and/or line extensions to support the initial offering?

·Road-mapping – Mapping out the way forward, setting goals and delivering a pathway to achieve the goals

· Gap Analysis – Analyzing the technical and technology gaps as well as understanding the Key Skills, attributes and knowledge of the people

· Risk Analysis – Measurement of the risk associated with the proposal, how to hedge against it, minimize and exploit.

Roche has teamed up with Warp Drive Bio to access novel classes of antibiotics. The Big Pharma will pay up to $387 million to license and advance certain classes from the more than 100 groups of possibly novel antibiotics Warp Drive is analyzing.

InflaRx has raised $55 million (€47 million) in a new funding round. The series D follows fast after InflaRx established the potential of its anti-human complement factor C5a monoclonal antibody IFX-1 with phase 2a data.

The National Institutes of Health (NIH) has enlisted the help of 11 top-tier biopharma companies as it pushes towards the goal of cutting the time it takes to bring new cancer immunotherapies to patients in half.

In 2013, Sanofi was running multiple clinical trials to establish fedratinib as the cornerstone of its oncology portfolio. Then, in the space of a week, the FDA ordered a clinical hold and Sanofi canned the JAK2 inhibitor. Now, members of the team who first developed fedratinib have brought it back from the dead.